Conditions: Atherosclerosis Ischemia Myocardial Infarction Cerebrovascular Accident
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 258
Healthy volunteers: no

Brief summary:
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).

Detailed description:

Arms:
arm 1: Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year arm 2: Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year

Interventions: intervention 1: Vorapaxar 2.5 mg intervention 2: Placebo
Intervention descriptions: intervention 1: Vorapaxar 2.5 mg oral tablet intervention 2: matching placebo oral tablet

Protocol document: